David Johnson Einstein, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 8 | 2022 | 10660 | 0.820 |
Why?
|
Terminal Care | 5 | 2017 | 1634 | 0.790 |
Why?
|
Urogenital Neoplasms | 1 | 2020 | 138 | 0.720 |
Why?
|
Androstenes | 2 | 2019 | 170 | 0.720 |
Why?
|
Receptors, Androgen | 3 | 2023 | 1063 | 0.710 |
Why?
|
Phenylurea Compounds | 1 | 2022 | 550 | 0.700 |
Why?
|
Compassionate Use Trials | 1 | 2018 | 48 | 0.690 |
Why?
|
Androgen Receptor Antagonists | 1 | 2019 | 117 | 0.690 |
Why?
|
Quinolines | 1 | 2022 | 738 | 0.630 |
Why?
|
Paternalism | 1 | 2016 | 46 | 0.600 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2021 | 769 | 0.580 |
Why?
|
Death | 2 | 2017 | 578 | 0.580 |
Why?
|
Telephone | 1 | 2019 | 630 | 0.550 |
Why?
|
Advance Directives | 1 | 2016 | 230 | 0.520 |
Why?
|
Empathy | 1 | 2018 | 445 | 0.510 |
Why?
|
Personal Autonomy | 1 | 2016 | 299 | 0.490 |
Why?
|
Kidney Neoplasms | 2 | 2022 | 4042 | 0.490 |
Why?
|
Cisplatin | 1 | 2019 | 1663 | 0.460 |
Why?
|
Physician-Patient Relations | 4 | 2021 | 3320 | 0.450 |
Why?
|
Facial Paralysis | 1 | 2015 | 325 | 0.420 |
Why?
|
Carcinoma, Renal Cell | 2 | 2022 | 2964 | 0.400 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2021 | 2094 | 0.390 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2022 | 3502 | 0.390 |
Why?
|
Sarcoidosis | 1 | 2015 | 524 | 0.380 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2022 | 8925 | 0.350 |
Why?
|
Immunotherapy | 4 | 2021 | 4118 | 0.350 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 4250 | 0.350 |
Why?
|
Internal Medicine | 1 | 2015 | 1006 | 0.330 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2015 | 919 | 0.320 |
Why?
|
Palliative Care | 2 | 2021 | 3289 | 0.300 |
Why?
|
Internet | 1 | 2019 | 3078 | 0.290 |
Why?
|
Neoplasms | 5 | 2021 | 20515 | 0.290 |
Why?
|
Medical Oncology | 1 | 2017 | 2114 | 0.280 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2020 | 5238 | 0.270 |
Why?
|
Decision Making | 2 | 2016 | 3828 | 0.260 |
Why?
|
Radium | 1 | 2023 | 55 | 0.230 |
Why?
|
Antineoplastic Agents | 3 | 2023 | 13732 | 0.230 |
Why?
|
Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2022 | 39 | 0.230 |
Why?
|
Thiohydantoins | 1 | 2021 | 20 | 0.210 |
Why?
|
Phenylthiohydantoin | 2 | 2019 | 193 | 0.210 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3894 | 0.200 |
Why?
|
Leuprolide | 1 | 2021 | 308 | 0.180 |
Why?
|
Tumor Microenvironment | 2 | 2021 | 3071 | 0.180 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2022 | 651 | 0.170 |
Why?
|
Quality of Life | 1 | 2019 | 11691 | 0.170 |
Why?
|
Neutropenia | 1 | 2023 | 875 | 0.170 |
Why?
|
Sickness Impact Profile | 1 | 2019 | 318 | 0.160 |
Why?
|
Nitriles | 2 | 2019 | 948 | 0.160 |
Why?
|
Humans | 28 | 2023 | 715124 | 0.160 |
Why?
|
Urothelium | 1 | 2019 | 288 | 0.150 |
Why?
|
Benzamides | 2 | 2019 | 1411 | 0.150 |
Why?
|
Genes, Tumor Suppressor | 1 | 2021 | 1095 | 0.150 |
Why?
|
Prednisone | 1 | 2021 | 1549 | 0.150 |
Why?
|
Erythema Nodosum | 1 | 2015 | 34 | 0.140 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1055 | 0.140 |
Why?
|
Prostatectomy | 2 | 2021 | 1804 | 0.140 |
Why?
|
Internship and Residency | 1 | 2015 | 5618 | 0.140 |
Why?
|
Serine | 1 | 2018 | 857 | 0.130 |
Why?
|
Drug Approval | 1 | 2022 | 871 | 0.130 |
Why?
|
Phylogeny | 1 | 2021 | 2799 | 0.130 |
Why?
|
Male | 16 | 2023 | 351081 | 0.120 |
Why?
|
Renal Insufficiency | 1 | 2019 | 804 | 0.120 |
Why?
|
Anecdotes as Topic | 1 | 2012 | 57 | 0.120 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 1544 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2020 | 1283 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 1 | 2022 | 2075 | 0.110 |
Why?
|
Ambulatory Care Facilities | 1 | 2017 | 888 | 0.100 |
Why?
|
Hospice Care | 1 | 2017 | 618 | 0.100 |
Why?
|
Professional-Patient Relations | 1 | 2016 | 727 | 0.100 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3702 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 3694 | 0.100 |
Why?
|
Virus Diseases | 1 | 2015 | 684 | 0.090 |
Why?
|
Biopsy | 1 | 2021 | 6750 | 0.090 |
Why?
|
Prognosis | 3 | 2020 | 29168 | 0.090 |
Why?
|
Survival Analysis | 2 | 2020 | 10531 | 0.090 |
Why?
|
Culture | 1 | 2012 | 643 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2862 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8674 | 0.080 |
Why?
|
Neovascularization, Pathologic | 1 | 2017 | 2713 | 0.070 |
Why?
|
Risk Assessment | 4 | 2021 | 23511 | 0.070 |
Why?
|
African Americans | 1 | 2020 | 5065 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2019 | 11192 | 0.060 |
Why?
|
Phenotype | 1 | 2021 | 16371 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2019 | 13573 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8016 | 0.060 |
Why?
|
Aged | 6 | 2021 | 162674 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11317 | 0.050 |
Why?
|
Kidney | 1 | 2017 | 6903 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18789 | 0.050 |
Why?
|
Autocrine Communication | 1 | 2022 | 178 | 0.050 |
Why?
|
United States | 2 | 2022 | 67665 | 0.050 |
Why?
|
Role | 1 | 2020 | 178 | 0.050 |
Why?
|
RNA, Double-Stranded | 1 | 2021 | 275 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 13268 | 0.050 |
Why?
|
Middle Aged | 5 | 2021 | 214871 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 557 | 0.040 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8912 | 0.040 |
Why?
|
Physicians | 1 | 2016 | 4341 | 0.040 |
Why?
|
Prospective Studies | 2 | 2021 | 51181 | 0.040 |
Why?
|
Mice, Inbred ICR | 1 | 2018 | 378 | 0.040 |
Why?
|
Interferons | 1 | 2021 | 679 | 0.040 |
Why?
|
Mitosis | 1 | 2023 | 1255 | 0.040 |
Why?
|
beta Catenin | 1 | 2022 | 1044 | 0.040 |
Why?
|
Cohort Studies | 1 | 2019 | 39804 | 0.040 |
Why?
|
Mutation | 1 | 2020 | 29442 | 0.040 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2020 | 715 | 0.030 |
Why?
|
Androgens | 1 | 2023 | 1234 | 0.030 |
Why?
|
Perception | 1 | 2021 | 1179 | 0.030 |
Why?
|
Signal Transduction | 1 | 2017 | 23973 | 0.030 |
Why?
|
Female | 3 | 2017 | 377334 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2842 | 0.030 |
Why?
|
Prostate | 1 | 2020 | 1605 | 0.030 |
Why?
|
Animals | 3 | 2023 | 170726 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1573 | 0.030 |
Why?
|
Prostate-Specific Antigen | 1 | 2020 | 2274 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6538 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2567 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2020 | 7051 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2020 | 1722 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4320 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8738 | 0.020 |
Why?
|
Genomics | 1 | 2020 | 5333 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2018 | 11766 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2021 | 62186 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 16943 | 0.010 |
Why?
|
Adult | 1 | 2015 | 212129 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 23283 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39285 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2020 | 20398 | 0.010 |
Why?
|
Mice | 1 | 2023 | 80995 | 0.010 |
Why?
|